195 related articles for article (PubMed ID: 26943991)
1. Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
Yardley DA; Dickson N; Drosick D; Earwood C; Inhorn R; Murphy P; Hainsworth JD
Clin Breast Cancer; 2016 Jun; 16(3):180-7. PubMed ID: 26943991
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Gradishar WJ; Kaklamani V; Sahoo TP; Lokanatha D; Raina V; Bondarde S; Jain M; Ro SK; Lokker NA; Schwartzberg L
Eur J Cancer; 2013 Jan; 49(2):312-22. PubMed ID: 22954665
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
Yardley DA; Zubkus JD; Eakle JF; Bechhold RG; Finney L; Daniel D; Daniel B; Hainsworth JD
Clin Breast Cancer; 2015 Aug; 15(4):251-8. PubMed ID: 25640059
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.
Ferrario C; Strepponi I; Esfahani K; Charamis H; Langleben A; Scarpi E; Nanni O; Miller WH; Panasci LC
PLoS One; 2016; 11(12):e0167906. PubMed ID: 27992451
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer.
Luu T; Frankel P; Chung C; Chow W; Mortimer J; Hurria A; Somlo G
Clin Breast Cancer; 2014 Apr; 14(2):94-100. PubMed ID: 24370210
[TBL] [Abstract][Full Text] [Related]
7. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
Roché H; De Benedictis E; Cottura E; Govi S; Dalenc F; Locatelli A; Deslandres M; Zambetti M; Gladieff L; Messina M; Gianni L
Clin Breast Cancer; 2012 Jun; 12(3):167-74. PubMed ID: 22607766
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Baselga J; Costa F; Gomez H; Hudis CA; Rapoport B; Roche H; Schwartzberg LS; Petrenciuc O; Shan M; Gradishar WJ
Trials; 2013 Jul; 14():228. PubMed ID: 23876062
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Yardley DA; Peacock NW; Shastry M; Burris HA; Bechhold RG; Hendricks CB; Yoshizawa CN; Sing AP; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(2):299-308. PubMed ID: 26507191
[TBL] [Abstract][Full Text] [Related]
11. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.
Moulder S; Li H; Wang M; Gradishar WJ; Perez EA; Sparano JA; Pins M; Yang X; Sledge GW
Breast Cancer Res Treat; 2010 Feb; 119(3):663-71. PubMed ID: 20012354
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
Spigel DR; Rubin MS; Gian VG; Shipley DL; Burris HA; Kosloff RA; Shih KC; Quinn R; Greco FA; Hainsworth JD
Lung Cancer; 2017 Nov; 113():79-84. PubMed ID: 29110854
[TBL] [Abstract][Full Text] [Related]
17. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
Smith JW; Vukelja S; Rabe A; Wentworth-Hartung N; Koutrelakos N; Shao SH; Whittaker T; Wang Y; Asmar L; McDowell DO; Mukhopadhyay P; O'Shaughnessy J
Breast Cancer Res Treat; 2013 Nov; 142(2):381-8. PubMed ID: 24166282
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
[TBL] [Abstract][Full Text] [Related]
19. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
20. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
